FDA Expands Tenofovir Alafenamide Indication to Treat HBV in Patients as Young as 6
March 28th 2024Tenofovir alafenamide was originally approved by the FDA in 2016 to treat adults with chronic HBV infection with compensated liver disease and in 2022 to treat pediatric patients aged 12 years and older.
Examining Trends in Long-Term Opioid Use, Importance of Pharmacist-Physician Collaboration
March 27th 2024At APhA 2024, 2 posters looked into how collaboration between physicians and community pharmacists is crucial when it comes to opioid prescriptions, and current opioid use patterns among older adults.
Psychedelic Therapeutics: Education, Advocacy Key to Overcoming Integration Hurdles
March 26th 2024According to Sa’ed Al-Olimat, education and advocacy are key to ensure a safe and accessible landscape of psychedelic therapeutics, especially as the compounds inch closer to the mainstream health care market.
Pharmacists Should Take a Proactive Approach When Addressing Controlled Substance Concerns
March 24th 2024At this year’s American Pharmacists Association Annual Meeting & Exposition, Mark Garofoli urged pharmacists to develop strong documentation practices and go beyond baseline federal regulations to care for patients with red flags.
How Emotional Intelligence Helps Pharmacists Handle Controlled Substance Concerns
March 23rd 2024Pharmacists must uphold their “corresponding responsibility” to address controlled substance concerns among patients while balancing safety and respect, said Mark Garofoli at this year’s American Pharmacists Association Annual Meeting & Exposition.